ROUNDUP/Aktien New York Schluss: Zugespitzter Handelsstreit belastet den Dow

DECN Increases Manufacturing Capacity, Opens International Markets for Popular GenUltimate!

Donnerstag, 01.12.2016 15:20 von PR Newswire

PR Newswire

LOS ANGELES, Dec. 1, 2016 /PRNewswire/ -- Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the GenUltimate!™ glucose test strip, designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets, today conveys recent marketing plan advancements, increases in manufacturing capabilities, and new international distributor additions.

Since the landmark conclusion of the successful litigation defense to the imaginary patent infringement allegations filed by J&J, the company has focused its energies and resources towards the precise execution of its formal marketing plan. Several recent communications to its shareholders and the broader investment community were highlighted by the pursuit and completion of the initial phase of that Plan. Hundreds of on-line retail merchandising venues had been added and through which Gen family of test strip revenue had begun flowing. That successful tactical campaign continues to increase distribution point locations and expand individual location footprint.  In anticipation of this accelerated demand, factory capacity has been increased by the Pennsylvania and the South Korea contract manufacturers to 620,000 GenUltimate! units per month.

Concurrent to that on-line escalation, the company initiated the second chapter of its detailed Plan with the targeting and contracting of a global network of international distributors. That network remains in development and its conclusion is not shortly expected, however, initial progress has yielded short term positive accomplishments; two of which the company would like to share with its loyal shareholders:

  • Uni-Care Corp

Seoul, South Korea

  • Macre Diagnosis S.R.L.

Santa Cruz, Bolivia

Keith Berman, PEO of Decision Diagnostics commented, "It is gratifying and highly appropriate that immediately following the Thanksgiving holiday we are in a position to update our shareholders and the entire investment community regarding the continuation of our efforts to execute our marketing plan, and to communicate the initial fruits of those tactical endeavors. We are all thankful for the loyalty of our investors and the support of our customers."

The Company has contracted Uni-Care Corp to exclusively distribute the Gen family of test strips to the Republic of South Korea, China and the Philippines.  Uni-Care has activated the arrangement with the submission of an initial stocking purchase order for approximately 40,000 pieces of GenUltimate!  test strips to be shipped immediately following the product's registration with South Korea's KFDA regulatory agency, expected in early December. Additional stocking orders are expected from sub-distributors in China and the Philippines.  The Uni-Care Exclusive Distribution Agreement requires the  annual purchase of a minimum of 250,000 GenUltimate! units in the next 12 months.

Macre Diagnostics S.R.L. has become the company's distributor to multiple countries in South America. Macre, located in Santa Cruz, Bolivia has secured its regulatory approvals and has placed an initial opening  order for 10,800 pieces of GenUltimate! with a 12 month cumulative order for 2,850,000 units of GenUltimate!

Forward-Looking Statements: 

This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of November 29, 2016, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.


Decision Diagnostics Corp. 
Keith Berman 
(805) 446-2973

To view the original version on PR Newswire, visit:

SOURCE Decision Diagnostics Corp.